A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...

Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of ...

The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

Most Wall Street professionals obsess over short-term returns. However, patient individual investors who buy and hold leading stocks on the cusp of new growth trends could strike it rich.

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 7 includes Village Super Market, MARA Holdings, ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval allows doctors to prescribe Ozempic specifically to lower the risk of kidney ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 4,16,368.59 Crore) operating in Pharmaceuticals sector. Sun Pharmaceutical ...